Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 (Becotatug Vedotin) in Relapsed Small Cell Lung Cancer
NCT07874581Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of becotatug vedotin in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Overall Survival at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07874581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874581.